J.G. Chemicals Limited

Chemicals | India

Leading zinc oxide manufacturer

About the Company

JG Chemicals Limited (JGCL) is one of the largest zinc oxide manufacturers in India and among the top 10 manufacturers of zinc oxides globally manufacturing through French process, the dominant production technology for producing zinc oxide adopted by all the major producers in Americas, Europe, and Asia with a market share of around 30% for FY22. It sells over 80 grades of zinc oxide, thereby enabling it to cater to a wide variety of customers, across various end-use industries, but derives 90% of the revenues from rubber and tyres industries. JGCL material subsidiary BDJ Oxides is the only zinc oxide manufacturing facility in India to have an IATF certification preferred by tyre manufacturers supplying to OEM.

Long term relationships and High barriers to entry

JGCL caters to a wide array of customers and has built a long-standing relationship with customers across end-user industries in the tyres, ceramics, rubber, paints, cosmetics and batteries industry. JGCL has marketed and sold products to over 200 domestic customers and over 50 global customers in more than 10 countries, suppliers to 9 out of top 10 global tyre manufacturers and to all of the top 11 tyre manufacturers in India over the last 3 years. The high cost of product development, complexity of the chemistry involved in innovating and tailoring products to the customised needs of customers, which requires necessary technical expertise and lengthy and stringent supplier qualification process are the other entry barriers in business.

Diversification and expansion of production facilities

The zinc oxide market in India is estimated to register around 10%-12% CAGR from FY22 to FY27. JGCL proposes to establish a green field manufacturing facility in the state of Gujarat to capture market share by catering to the needs of the ceramics, pharmaceuticals and tyre industries, which have a presence in the western part of India. JGCL constantly seeks to introduce new product verticals and develop our product capabilities to distinguish ourselves from our competitors to enhance the product portfolio for industries like ceramics, pharmaceuticals & cosmetics, paints & coatings, agrochemicals, nutraceuticals, animal feed and batteries.

Financials in Brief

On the financial front, JGCL has reported a turnover of Rs 435.3 Crs, Rs. 612.8 Crs and Rs 784.6 Crs for FY21, FY22 and FY23 respectively. The company reported profit of Rs28.8 Crs, Rs43.1 Crs and Rs56.8 Crs for the respective periods. It has recorded a healthy Revenue, EBITDA and PAT CAGR of 34%, 32% and 40% respectively over FY21-23. For the last three fiscals, the company has reported an average EPS of Rs.11 on diluted basis and an average RoNW of 30% and is expected to improve further with improvement in capacities, lower interest and new products improving margins.

Our View

JGCL enjoys a leading market position with a diversified customer base and multiple products and has long term association with key customers in ZnO for end-user industries like tyres, ceramics, paints, footwear, cosmetics etc. JGCL is expanding its footprints, diversifying products in new verticals, improving capacity utilization with strong demand, and focusing on R&D to support complex chemistries and cost efficiencies thereby improving the margin acceleration over the next few years. We believe with an experienced management team, strong financials of 34% CAGR in revenues and 40% CAGR in profits for FY21-23 and strong growth levers ahead. **Hence, we recommend "SUBSCRIBE" to the issue.**



IPO Details

Implied Market Cap (Rs Crs)*	866		
QIB / HNI / Retail	50%/15%/35%		
Minimum Bid Qty. (Nos)	67		
Total Issue (Crs)	251.2		
OFS (Crs)	86.2		
Fresh Issues (Crs)	165.0		
Issue Open/Closing Date	05-Mar-24/07-Mar-24		
Face Value (Rs)	10		
Price Band (Rs)	210-221		

*At higher band

Object of the Issue

- Funding working capital and R&D centre.
- Repayment of certain borrowings.
- General Corporate purposes.

Strengths

- Leading market position with a diversified customer base.
- Long-term relationships with suppliers & having robust supply chain.
- High entry barriers in key end-use industries.

 Experienced and dedicated management team with strong financials.

Key Risk

- Dependency on single product to single end user, i.e tyres industries.
- Higher input prices denting margins.

Shareholding (%)	Pre-Issue	Post-Issue
Promoters	100.0	71.0
Others	0.0	29.0

Key Financials

(Rs Crs)	FY22(12)	FY23(12)	9MFY24
Capacity Utilisation (%)	63.4	57.4	52.1
Revenue	612.8	784.6	486.3
EBITDA	66.4	85.1	32.9
EBITDA Margin (%)	10.8%	10.8%	6.8%
PAT	43.1	56.8	18.5
PAT Margin (%)	7.0%	7.2%	3.8%
EPS (Rs)	11.00	14.5	4.7*
RocE (%)	25.9	29.4	11.9*
RoE (%)	30.6	30.5	8.2*
Net Worth	147.7	199.9	217.8
Total Borrowings	93.9	70.3	24.9

Source: RHP, Note: *9M Not annualised

Senior Research Analyst: Vikas Jain Contact : (022) 41681371 Email : vikas.i.jain@relianceada.com

Exhibit 1: Corporate Structure




Exhibit 2: Manufacturing Process








Exhibit 3: Trend in global chemical sales (USD billion)

Source: RHP, CEFIC, CareEdge Research

Exhibit 4: Country-wise international chemical sales (USD billion)






Exhibit 5: Outlook for Indian automobile industry production (in million units)

Source: RHP, CareEdge Research estimates and SIAM

3

Disclaimer:

Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India's leading retail broking houses. Reliance Capital is amongst India's leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website www.reliancecapital.co.in. RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014

General Disclaimers: This Research Report (hereinafter called 'Report') is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report.

Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely affected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces affecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be affected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may affect the pricing of derivatives.

Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/ or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Disclosure of Interest: The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL's Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage or non brokerage services.RSL, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report.

The research analysts has served as an officer, director or employee of the said issuer company(ies)?: No

RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No

Copyright: The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL.

RSL's activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/ strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report.

Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of.

RSL CIN: U65990MH2005PLC154052. SEBI registration no. (Stock Broker: INZ000172433, Depository Participants: CDSL IN-DP-257-2016 IN-DP-NSDL-363-2013, Research Analyst: INH000002384); AMFI ARN No.29889.

4